The acceleration of climatic, digital, and health challenges is testing scientific communities. Scientists must provide concrete answers in terms of technological solutions to a society which expects immediate returns on the public investment. We are living such a scenario on a global scale with the pandemic crisis of COVID-19 where expectations for virological and serological diagnosis tests have been and are still gigantic. In this Perspective, we focus on a class of biosensors (mechanical biosensors) which are ubiquitous in the literature in the form of high performance, sensitive, selective, low-cost biological analysis systems. The spectacular development announced in their performance in the last 20 years suggested the possibility of finding these mechanical sensors on the front line of COVID-19, but the reality was quite different. We analyze the cause of this rendez-vous manqué, the operational criteria that kept these biosensors away from the field, and we indicate the pitfalls to avoid in the future in the development of all types of biosensors of which the ultimate goal is to be immediately operational for the intended application.

中文翻译：

---

MEMS 生物传感器和 COVID-19：错失良机

气候、数字和健康挑战的加速正在考验科学界。科学家必须为期望公共投资立即获得回报的社会提供技术解决方案的具体答案。在全球范围内，我们正经历着这样一种场景，即新冠肺炎 (COVID-19) 大流行危机，人们对病毒学和血清学诊断测试的期望无论过去还是现在都很高。在本视角中，我们重点关注一类生物传感器（机械生物传感器），它们以高性能、灵敏、选择性、低成本的生物分析系统的形式在文献中无处不在。过去 20 年来，其性能取得了惊人的发展，这表明有可能在 COVID-19 的前线找到这些机械传感器，但现实却截然不同。我们分析了这种集合点错误的原因，使这些生物传感器远离现场的操作标准，并指出了未来在开发所有类型的生物传感器时要避免的陷阱，其最终目标是立即可用于预期应用。